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OBJECTIVES: Two human papillomavirus (HPV) cervical cancer (CC) vaccines are 
currently available: a bivalent HPV-16/18 vaccine and a quadrivalent HPV-6/11/16/18 
vaccine. The quadrivalent vaccine has an additional effect against genital warts, while 
the other offers broader protection against oncogenic non-vaccine types (cross-protec-
tion). The annual cost-consequences of both vaccines on HPV-related morbidity (i.e. 
abnormal pap smears, CIN1, CIN2/3 lesions, CC and genital warts) were evaluated 
within three European countries: Italy, UK and the Netherlands. METHODS: A 
static population model was developed in Excel®. The two vaccines differ in cross-
protection level based on the latest results from clinical trials using, for both, the 
HPV naïve population (without current or past HPV infection) and country speciﬁc 
HPV-type distribution in each related lesion. Costing was performed from a health 
care perspective and obtained from published sources and ofﬁcial tariff data. No dis-
counting was applied as results are reported over one year after reaching steady state. 
RESULTS: The more cross protection observed with the bivalent vaccine leads to an 
additional reduction in 9 510, 22 189, and 781 abnormal pap smears respectively in 
Italy, UK and the Netherlands; 275, 22,951, and 184 CIN1; 1,479, 8,693, and 833 
CIN2/3; and 345, 142, and 28 CC cases while the quadrivalent vaccine results in 
23,260, 50,324, and 2,983 genital wart cases prevented per year. More cost was saved 
with the bivalent compared with the quadrivalent vaccine and the amount per country 
per year was estimated at a2,719,040, £22,044,085, and a1,951,369 respectively. 
CONCLUSIONS: Within the Italian, the UK and the Netherlands settings the addi-
tional level of cross protection of the bivalent vaccine allows for more reduction in 
CC and HPV-related morbidity resulting in more cost savings that completely offset 
the beneﬁt the quadrivalent vaccine has in preventing genital warts.
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OBJECTIVES: Bevacizumab (Bev) has been shown to increase progression free sur-
vival (PFS) when combined with cisplatin-gemcitabine (Reck 2009) and PFS and 
overall survival in combination with carboplatin-paclitaxel (Sandler 2006) when com-
pared with chemotherapy (CT) alone. Cetuximab (Cet) has also improved outcomes 
in these patients when combined with vinorelbine and cisplatin (VinCis) (Pirker 2009). 
The aim of this analysis is to compare the administration costs of BevCT and Cet-
VinCis therapy for mNSCLC patients in France, Germany, and Spain. METHODS: 
A systematic literature search performed in Medline, Embase, Cochrane, and Centre 
for Reviews and Dissemination databases identiﬁed 578 publications which included 
administration costs. Two independent reviewers selected sixteen full text publications 
for inclusion. In addition, an evaluation of national reimbursement tariffs in both 
inpatient and outpatient settings was performed. Alongside this, in-depth semi-struc-
tured interviews were conducted with ﬁve expert oncologists in three countries to 
verify cost ﬁndings and reimbursement structures. RESULTS: For induction therapy, 
when comparing CetVinCis versus BevPacCarbo or BevGemCis respectively, the incre-
mental administration cost per mNSCLC patient is an additional a4500/a2250 in 
France, a7320/a3660 in Germany, and a3960/a1980 in Spain for the CetVinCis 
 combination vs administration costs for the Bev combinations. When considering 
additional maintenance monotherapy the difference is a6,375/a4,125 in France, 
a10,370/a6,710 in Germany, and a5,610/a3,630 in Spain with again higher costs 
associated with the CetVinCis combination vs the Bev combinations. Variation in cost 
is attributable to increased number of patient visits and disparities in reimbursement 
structures. CONCLUSIONS: Additional injection visits associated with CetVinCis 
therapy (weekly for cetuximab vs once every three wekks for Bev) are a cost driver in 
the treatment of mNSCLC. BevPacCarbo or BevGemCis when compared with Cet-
VinCis offers a less often and more convenient dosing regime, while also incurring 
fewer administration costs.
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OBJECTIVES: Extended 7-year follow-up of the US Oncology Adjuvant Trial 9735 
demonstrated that TC (docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/ m2 every 
21 days for 4 cycles) signiﬁcantly improves disease-free survival (DFS) and overall 
survival (OS) compared to AC (doxorubicin 60 mg/m2 plus cyclophosphamide 
600 mg/m2 every 21 days for 4 cycles) as adjuvant treatment of operable invasive 
breast cancer. Cost-effectiveness analyses of TC versus AC were conducted from a US 
and Canadian payer perspective, based on data from Trial 9735. METHODS: A 
Markov model was developed to estimate incremental cost per life year gained and 
quality-adjusted life year (QALY) gained over a lifetime horizon. Monthly survival 
and risk of disease recurrence were estimated for up to 7 years using OS and DFS 
from Trial 9735. Survival was extrapolated to lifetime using estimates of general 
population life expectancy, assuming no treatment beneﬁt beyond the trial period. 
Country-speciﬁc resource utilization and unit costs were applied to estimate costs (in 
2008 dollars) for chemotherapy administration, chemotherapy-related toxicities, 
recurrence and adverse events. Utility weights used in the calculation of QALYs were  
derived from the literature. RESULTS: For the US analysis, the lifetime cost per life 
year gained (TC vs. AC) was US$6261 and cost per QALY gained was US$7905 (3% 
annual discount rate). For the Canadian analysis, the lifetime cost per life year gained 
was CAN$6842 and cost per QALY gained was CAN$8251 (5% annual discount 
rate). The results were robust across a range of sensitivity analyses. CONCLUSIONS: 
In patients with operable invasive breast cancer, adjuvant treatment with TC provides 
gains in terms of life years and QALYs compared to AC and results in very favourable 
cost-effectiveness ratios. TC is a clinically and economically attractive alternative to 
AC for patients receiving adjuvant chemotherapy for operable breast cancer in North 
America.
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OBJECTIVES: The randomized CHAT trial (N  222) comparing trastuzumab and 
docetaxel either with capecitabine (HTX) or without (HT) as ﬁrst-line therapy for 
HER2mBC, demonstrated signiﬁcantly superior progression-free survival (PFS) and 
a trend towards improved overall (OS)survival with HTX after 2 years of follow-up. 
This economic analysis was conducted to evaluate the cost-effectiveness of adding 
capecitabine to HT in these patients in Spain, France and Italy. METHODS: A 
Markov-model was constructed to estimate OS and PFS for a 10-year time horizon 
using a parametric extrapolation of PFS data from the CHAT-trial and identical 
transition probabilities from progression to death in both arms. Costs for drug use, 
administration, treatment of adverse events and supportive care were included. A 
probabilistic sensitivity analysis was conducted to account for uncertainty. RESULTS: 
Adding capecitabine to HT resulted in 0.4 (95%CI: 0.03–0.84) additional years of 
PFS and 0.4 (95%CI: 0.0–0.73) additional life years gained (LYG). Mean total costs 
increased by a5,500 (95%CI: 6,012–17,918) in the HTX-arm for France, a4,200 
(95%CI: 5,700–14,690) for Spain and a3,100 (95%CI: 3,626–10,770) for Italy. 
This increase was mainly due to costs for capecitabine and trastuzumab (higher 
cumulative dose in the HTX-arm), although approximately 40% of these additional 
costs were compensated by reduced dosage and costs from docetaxel. Costs per PFS-
year amounted to a13,000 (France), a10,000 (Spain) and a7,500 (Italy). Costs per 
LYG were a15,400 (France), a11,900 (Spain) and a8,900 (Italy). More patients in 
the HT-arm (18 vs. 10) received trastuzumab for the treatment of progression. These 
additional costs were not included in the analysis. CONCLUSIONS: HTX signiﬁcantly 
improved outcomes for patients compared with HT. A partial cost-offset due to the 
reduction of docetaxel dosage contributes to the overall cost-effectiveness of adding 
capecitabine to HT for ﬁrst-line treatment of HER2mBC, even without considering 
costs for the treatment of progression.
